DK0641567T3 - Stabile farmaceutiske præparater indeholdende hybrid alfa-interferon - Google Patents

Stabile farmaceutiske præparater indeholdende hybrid alfa-interferon

Info

Publication number
DK0641567T3
DK0641567T3 DK94305930T DK94305930T DK0641567T3 DK 0641567 T3 DK0641567 T3 DK 0641567T3 DK 94305930 T DK94305930 T DK 94305930T DK 94305930 T DK94305930 T DK 94305930T DK 0641567 T3 DK0641567 T3 DK 0641567T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparations
preparations containing
hybrid alpha
stable pharmaceutical
alpha interferon
Prior art date
Application number
DK94305930T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Lowther
John Douglas Allen
Colin Howes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316849A external-priority patent/GB9316849D0/en
Priority claimed from GB9405879A external-priority patent/GB9405879D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0641567T3 publication Critical patent/DK0641567T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK94305930T 1993-08-13 1994-08-10 Stabile farmaceutiske præparater indeholdende hybrid alfa-interferon DK0641567T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316849A GB9316849D0 (en) 1993-08-13 1993-08-13 Pharmaceutical compositions
GB9405879A GB9405879D0 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK0641567T3 true DK0641567T3 (da) 2000-08-14

Family

ID=26303371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94305930T DK0641567T3 (da) 1993-08-13 1994-08-10 Stabile farmaceutiske præparater indeholdende hybrid alfa-interferon

Country Status (19)

Country Link
US (1) US5609868A (de)
EP (1) EP0641567B1 (de)
JP (1) JP3745395B2 (de)
KR (1) KR100351495B1 (de)
AT (1) ATE190498T1 (de)
AU (1) AU679233B2 (de)
CA (1) CA2129921C (de)
CY (1) CY2230B1 (de)
DE (1) DE69423402T2 (de)
DK (1) DK0641567T3 (de)
ES (1) ES2144034T3 (de)
FI (1) FI111222B (de)
GR (1) GR3033239T3 (de)
HU (1) HU224613B1 (de)
IL (1) IL110566A (de)
NO (1) NO315843B1 (de)
NZ (1) NZ264218A (de)
PT (1) PT641567E (de)
TW (1) TW249202B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102236A1 (en) * 1994-12-08 2002-08-01 Taylor Peter William Liposomal interferon hybrid compositions
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EE04223B1 (et) * 1996-12-24 2004-02-16 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
IL155788A0 (en) 2000-11-07 2003-12-23 Chiron Corp Stabilized interferon compositions
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
BRPI0613098A2 (pt) * 2005-06-29 2010-12-21 Yeda Res & Dev mutantes de interferon a2 (ifna2) recombinantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196823A (ja) * 1983-04-20 1984-11-08 Sunstar Inc 皮膚および粘膜の真菌症治療用外用剤
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
EP0196203A3 (de) * 1985-03-25 1987-09-30 Schering Corporation Stabile gamma-Interferon-Formulierung
EP0205404B1 (de) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid-Interferone
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.

Also Published As

Publication number Publication date
CA2129921C (en) 2006-12-05
HUT68692A (en) 1995-07-28
KR100351495B1 (ko) 2003-02-19
HU9402356D0 (en) 1994-10-28
AU679233B2 (en) 1997-06-26
ES2144034T3 (es) 2000-06-01
HU224613B1 (hu) 2005-11-28
EP0641567B1 (de) 2000-03-15
FI943705A0 (fi) 1994-08-10
EP0641567A1 (de) 1995-03-08
CA2129921A1 (en) 1995-02-14
PT641567E (pt) 2000-08-31
JP3745395B2 (ja) 2006-02-15
FI943705A (fi) 1995-02-14
AU6893994A (en) 1995-02-23
NO942983L (no) 1995-02-14
DE69423402D1 (de) 2000-04-20
JPH07145070A (ja) 1995-06-06
US5609868A (en) 1997-03-11
NO942983D0 (no) 1994-08-12
DE69423402T2 (de) 2000-08-03
IL110566A (en) 1999-12-22
TW249202B (de) 1995-06-11
IL110566A0 (en) 1995-01-24
NO315843B1 (no) 2003-11-03
ATE190498T1 (de) 2000-04-15
KR950005325A (ko) 1995-03-20
FI111222B (fi) 2003-06-30
CY2230B1 (en) 2003-04-18
GR3033239T3 (en) 2000-09-29
NZ264218A (en) 1995-07-26

Similar Documents

Publication Publication Date Title
MA23838A1 (fr) Solution aqueuse d'interferon x
ITMI941891A0 (it) 3-aril-benzofuranoni come agenti stabilizzanti
DE69330180T2 (de) Hyaluronsäure enthaltende formulierungen
FI933565A (fi) 7-(substituerad)-9-((substituerad glycyl)amido)-6-demetyl-6-deoxitetracykliner
DE69325944D1 (de) s-Triazinderivate als Lichtschutzmittel
DE69132435D1 (de) Inhibitoren retroviraler Proteasen
NO932873D0 (no) 9-((substituerte glycyl)amido)-6-dementyl-6-deoksotetrasykliner
FI960253A0 (fi) Aerosolisoitujen proteiinien stabilointi
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
DE69202164T2 (de) Stabilisierung von Thiolenzusammensetzungen.
DK0641567T3 (da) Stabile farmaceutiske præparater indeholdende hybrid alfa-interferon
DK0408371T3 (da) Hæmoregulatoriske peptider
ES2060689T3 (es) Alcoholes peptidicos anticoagulantes.
DE59307366D1 (de) Dithiolanylglycinhaltige HIV-Proteaseinhibitoren vom Hydroxyethylenisostertyp
ES2123728T3 (es) Derivados de pirrolo-pirazina de actividad 5-ht3.
MA23133A1 (fr) Derives d'acide d'acyloxyhexanoique .
DE69212267T2 (de) Echinocandin-B-Derivat
DE69817915D1 (de) Harnstoff- und Thioharnstoffderivate von antibiotisch wirksamen Glykopeptiden
DE69431289D1 (de) Stabilisierung von Prostansäurederivaten
GR1001368B (el) Φαρμακευτικοί φορείς.
ITRM920430A1 (it) Composizioni stabilizzate di hdag.
NO931096D0 (no) Injeksjonssproeyte for engangsbruk